GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lukas Biomedical Inc (ROCO:6814) » Definitions » Equity-to-Asset

Lukas Biomedical (ROCO:6814) Equity-to-Asset : 0.67 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Lukas Biomedical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lukas Biomedical's Total Stockholders Equity for the quarter that ended in Jun. 2023 was NT$312.8 Mil. Lukas Biomedical's Total Assets for the quarter that ended in Jun. 2023 was NT$466.4 Mil. Therefore, Lukas Biomedical's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.67.

The historical rank and industry rank for Lukas Biomedical's Equity-to-Asset or its related term are showing as below:

ROCO:6814' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51   Med: 0.56   Max: 0.7
Current: 0.67

During the past 5 years, the highest Equity to Asset Ratio of Lukas Biomedical was 0.70. The lowest was 0.51. And the median was 0.56.

ROCO:6814's Equity-to-Asset is ranked better than
50.1% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:6814: 0.67

Lukas Biomedical Equity-to-Asset Historical Data

The historical data trend for Lukas Biomedical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lukas Biomedical Equity-to-Asset Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
0.66 0.54 0.56 0.54 0.68

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.54 0.70 0.68 0.67

Competitive Comparison of Lukas Biomedical's Equity-to-Asset

For the Biotechnology subindustry, Lukas Biomedical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lukas Biomedical's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's Equity-to-Asset falls into.



Lukas Biomedical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Lukas Biomedical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=327.485/479.666
=0.68

Lukas Biomedical's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=312.78/466.413
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lukas Biomedical  (ROCO:6814) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Lukas Biomedical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Lukas Biomedical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lukas Biomedical (ROCO:6814) Business Description

Traded in Other Exchanges
N/A
Address
Xinyi Road, Da'an District, 3rd Floor, No. 2, Lane 265, Section 4, Taipei, TWN
Lukas Biomedical Inc is engaged in the research and development of immunotherapy for cancer treatment technologies. It researches on the Memory T cell (LuLym-T) to improve the clinical outcome of cancer treatment.

Lukas Biomedical (ROCO:6814) Headlines

No Headlines